Guests:

Dr Lara Briden

Naturopathic doctor and Bestselling Author

Instagram: www.instagram.com/larabriden/

Website: www.larabriden.com/

Dr Molly Maloof

Educator, Author, and Founder of Adamo

Instagram: www.instagram.com/drmolly.co/?hl=en

Website: https://drmolly.co/

______________________

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.

Link: www.getstride.com/unlocked/

______________________

What if the key to female longevity has been hiding in plain sight?

In this episode, Phil Newman and Dr Nina Patrick sits down with Dr Lara Briden, evolutionary biologist and hormone expert, and Dr Molly Maloof, functional medicine practitioner, to explore the metabolic, hormonal, and evolutionary factors that shape female longevity.

They dive into the often-overlooked role of iron in perimenopause and post-menopause, the hidden epidemic of insulin resistance, and the nuanced balance of fatty acids for cellular health. Lara reframes menopause as an adaptive stage that supports the survival of the next generation, while Molly explains why metabolic flexibility is one of the most powerful tools for long-term health.

Together, they discuss practical strategies women can use across their lifespan—from iron management and blood markers to gut health, nutrition, and exercise—as well as exciting breakthroughs in biotechnology, peptides, and regenerative medicine that could extend female healthspan in the next decade.

In this episode, you’ll learn:

• Why managing iron levels is crucial for longevity, especially in perimenopause and post-menopause.
• How regular ovulatory cycles and pregnancy shape long-term metabolic and reproductive health.
• The hidden role of insulin resistance and simple blood markers that can flag early metabolic dysfunction.
• The importance of omega-6, omega-3, and saturated fats balance for cell membrane and neurological health.
• How evolutionary biology explains menopause as a “superpower” for human survival.
• Practical steps for women to optimize metabolism, exercise, and nutrient intake across their lifespan.
• The emerging role of biotechnology, regenerative medicine, and peptides in extending female healthspan.

If you want to take control of your metabolic health, understand menopause as a stage of strength, and learn strategies to optimize female longevity across the lifespan, this is a conversation you don’t want to miss.

Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the emerging strategies and interventions shaping the future of female health.

______________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY

⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.

Link: https://www.getstride.com/unlocked/

______________________

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore new research shaping the future of longevity science, from macrocyclic peptides targeting previously undruggable diseases to hyperbaric oxygen therapy in performance and longevity, and South Korea emerging as a global biotech hub.

• Santa Cruz-based Unnatural Products raised $45 million in Series B funding and secured a potential $1.7 billion collaboration with Novartis. The company develops macrocyclic peptide therapeutics, molecules that combine the selectivity of biologics with the cell permeability of small molecules, targeting age-related cardiometabolic, inflammatory, and immunological diseases.
• Hyperbaric oxygen therapy (HBOT) is moving into the longevity and biohacking space, with companies like HPO.TECH’s launching chambers for performance and wellness settings. Early anecdotal reports suggest improvements in sleep and cognition, but long-term, large-scale clinical evidence is still limited.
• South Korea is quietly becoming a major longevity hub. Eli Lilly and Roche have invested nearly $1 billion in local biotech infrastructure, including incubation programs and advanced hospitals.
• Serotonin Centers launches a partner program bringing medically supervised longevity services directly into gyms across the US. By integrating diagnostics, therapies, and biomarker-driven programs into existing fitness spaces, this model increases accessibility and scalability for preventive health, bridging the gap between clinical longevity interventions and everyday fitness routines.
• The Aging Research & Drug Discovery (ARDD) conference is relocating to Boston in 2026, placing one of the world’s leading longevity science meetings directly in the heart of a dense biotech, pharma, and academic corridor. This move strengthens connections between research, startups, and decision-makers, accelerating deal flow and industry engagement while highlighting the mainstreaming of aging biology into drug development pipelines.
• Evolve Science has launched a US-based longevity peptide platform designed around medically supervised protocols targeting core aging pathways, including tissue repair, mitochondrial function, and metabolic regulation. By combining proper manufacturing, analytics, and clinical follow-up, the platform aims to separate validated therapeutic peptides from gray-market hype, addressing the growing demand for safe, evidence-based interventions in the longevity space.

______________________

News & References:

• Engineering longevity with the ZEUGMA hyperbaric chamber → https://longevity.technology/news/engineering-longevity-with-the-zeugma-hyperbaric-chamber/
• Biotech lands $45m to drug the undruggable → https://longevity.technology/news/biotech-lands-45m-to-drug-the-undruggable/
• Gyms tap medical longevity with Serotonin Centers’ model → https://longevity.technology/news/gyms-tap-medical-longevity-with-serotonin-centers-model/
• Lilly commits $500m in South Korea’s rise as longevity hub → https://longevity.technology/news/lilly-commits-500m-in-south-koreas-rise-as-longevity-hub/
• ARDD 2026 to relocate to Boston → https://longevity.technology/news/ardd-2026-to-relocate-to-boston/
• Evolve Science launches longevity peptide platform → https://longevity.technology/news/evolve-science-launches-longevity-peptide-platform/

______________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Guests:

Dr. Dave Rabin MD, PhD

Founder of Apollo Neuro

Linkedin: www.linkedin.com/in/drdavemdphd/

Website: https://apolloneuro.com/

Dr Pedram Shojai

Founder of The Urban Monk

Instagram:www.instagram.com/drpedramshojai/

Website: https://theurbanmonk.com/

___________________

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.

Link: www.getstride.com/unlocked/

___________________

What if stress isn’t something to eliminate… but something to train?

Phil Newman and Dr. Nina Patrick sit down with neuroscientist and psychiatrist Dr. Dave Rabin and physician and Qigong teacher Dr. Pedram Shojai to explore how resilience is built through the nervous system. From circadian rhythms and recovery to breathwork, movement, and biofeedback, they explain why longevity depends less on constant performance and more on structured restoration.

Dave explains how chronic uncertainty activates threat responses in the brain, disrupting sleep, focus, immunity, and emotional regulation. Predictability, safety signals, and vagus nerve activation help restore recovery pathways that support cognition and long term health.

Pedram shares how attention, perception, and daily pacing influence vitality. Practices like mindfulness, Qigong, and intentional routines help shift the body out of survival mode, while technology can support awareness but cannot replace foundational habits.

Together, they show that resilience is not a hack. It is a rhythm between effort and recovery that trains the brain to adapt, learn, and age well.

In this episode, you’ll learn:

• How chronic stress alters brain function, sleep, and long-term health
• Why recovery should be scheduled like performance
• How breathwork and somatic practices activate safety pathways
• The role of circadian rhythm in resilience and cognition
• Where wearable technology helps and where it doesn’t

If you want to understand how stress regulation shapes cognitive performance, sleep quality, and healthy aging, this episode connects neuroscience with practical daily habits you can actually apply.

Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the systems shaping how we live longer and better.

___________________

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: https://qrco.de/bgXpKn

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore new research shaping the future of longevity science, from neuroprotective obesity drugs and fasting-mimicking supplements to bionic vision implants and AI-driven athletic longevity platforms.

• A growing body of research suggests that GLP-1 receptor agonists may influence brain aging. A recent review in the Journal of Clinical Investigation highlights how these drugs could support neuronal energy production, stimulate autophagy, reduce chronic inflammation, and improve synaptic resilience. Early human studies show signals of preserved brain metabolism in Alzheimer’s patients, though larger clinical trials are still underway.
• New diagnostic tools for neurodegeneration are also emerging. Startup Amydis received funding from the National Institute on Aging to develop an eye-based molecular imaging test for Amyotrophic Lateral Sclerosis (ALS). Their approach uses fluorescent tracers that bind to TDP-43, allowing early disease signatures to be detected through routine retinal imaging.
• In metabolic health, Mimio Health reported results from a randomized controlled trial testing a fasting-mimetic supplement. The formulation includes Spermidine and Nicotinamide, compounds that rise during prolonged fasting. Over eight weeks, participants showed improvements in fasting glucose and lipid markers, suggesting the possibility of replicating certain fasting signals without caloric restriction.
• Hardware innovation is also advancing longevity care. Science Corporation raised $230 million to scale its PRIMA retinal implant, a tiny photovoltaic chip placed beneath the retina. Working with specialized glasses that project infrared patterns, the implant converts light signals into electrical stimulation, restoring basic visual perception for patients with advanced geographic atrophy.
• In sports longevity, Capriroso launched a new training intelligence system designed for endurance athletes. By combining sleep metrics, heart rate variability, training load, and recovery data, the platform aims to optimize performance across decades rather than short-term race cycles.
• Finally, emerging research into sleep and circadian biology continues to reshape dementia prevention strategies. Studies show that disrupting circadian rhythms can trigger inflammatory changes in brain immune cells known as microglia, which may contribute to neurodegenerative disease. Researchers are also studying hibernating animals to understand how certain species tolerate extreme metabolic stress and reverse neurological damage, offering potential new targets for human therapies.

_____________________

News & References:

• GLP-1 drugs hint at protection against neurodegeneration → https://longevity.technology/news/glp-1-drugs-hint-at-protection-against-neurodegeneration/
• Amydis lands NIA funding to detect ALS in the eye → https://longevity.technology/news/amydis-lands-nia-funding-to-detect-als-in-the-eye/
• Fasting mimetic shows metabolic effects in trial → https://longevity.technology/news/fasting-mimetic-shows-metabolic-effects-in-trial/
• Science Corp lands $230m to commercialize vision restoration chip → https://longevity.technology/news/science-corp-lands-230m-to-commercialize-vision-restoration-chip/
• Capriroso launches platform for athlete longevity → https://longevity.technology/news/capriroso-launches-platform-for-athlete-longevity/
• Sleep rhythms and dementia risk link emerges → https://longevity.technology/news/sleep-rhythms-and-dementia-risk-link-emerges/

_____________________

Hosts:

Phil Newman: ⁠⁠⁠⁠https://qrco.de/bgXpNY⁠⁠⁠⁠

Nina Patrick: ⁠⁠⁠⁠https://qrco.de/bgXpKn⁠

Guests:

Dr James Goolnik

Founder of Optimal Dental Health

Instagram: www.instagram.com/jamesgoolnik/?hl=en

Website: www.optimaldentalhealth.co.uk/

Dr Aoife Stack

Co-founder of Airway School

Instagram: www.instagram.com/doctor_aoife/?hl=en

Website: www.airwayschool.co.uk

______________________

What if your mouth was more than just teeth and gums? What if it silently shaped your sleep, metabolism, immunity, and brain health?

Phil Newman and Dr. Nina Patrick sit down with Dr. Aoife Stack and Dr. James Goolnik, two clinicians taking a systems-level approach to oral health. They explore how the mouth and airway influence sleep, metabolism, inflammation, and brain function, and why dental care isn’t just about teeth.

Aoife explains the importance of nasal breathing, tongue posture, and myofunctional therapy for optimal sleep and overall health. James highlights practical strategies around sugar reduction, saliva balance, and oral hygiene that protect against decay and inflammation. Together, they unpack the science connecting oral health with the microbiome, nitric oxide production, and systemic resilience.

The conversation dives into childhood and adult interventions—from simple nasal tape and tongue exercises to orthodontics and myofunctional therapy—showing how small adjustments can create meaningful improvements in energy, cognitive function, and long-term health. They also discuss how lifestyle factors, dietary habits, and awareness of daily routines can prevent cascading health issues before they start.

This episode emphasizes that longevity is more than exercise and diet. Supporting oral and airway health, understanding systemic connections, and applying practical, sustainable habits are essential pillars for extending healthspan, optimizing sleep, and improving quality of life.

In this episode, you’ll learn:

• Why nasal breathing, tongue posture, and oral function are foundational to sleep, energy, and brain health
• How simple practices like tongue scraping, nasal tape, and myofunctional exercises can improve airway and posture
• The role of saliva, oral microbiome, and diet in preventing decay, gum disease, and systemic inflammation- How small childhood and adult interventions can create long-term benefits for airway function, sleep quality, and resilience
• Strategies for sustainable sugar reduction and habit stacking to protect oral and systemic health

If you care about improving long-term health, sleep, and energy, and want actionable advice grounded in evidence-based science, this conversation is a must-listen.

Subscribe for weekly episodes that explore longevity science, preventative strategies, and the emerging tools and interventions that help us understand and optimize the body’s natural systems for lasting healthspan.

______________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY

⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest breakthroughs shaping longevity and proactive healthcare. From government-backed healthspan trials to next-generation brain wearables, smartphone-based health screening, ovarian longevity research, and nanotech biosensing, this episode connects science, innovation, and real-world impact.

• The US government committed $144 million through ARPA-H’s PROSPR program to fund research proving that aging can be treated in humans. Cambrian BioPharma received $30.8 million for trials of a next-generation rapamycin analog, while Linnaeus Therapeutics received $22 million to explore oncology-derived drugs showing age-related benefits. PROSPR also funds biomarker development and trial infrastructure to enable rapid, large-scale healthspan studies.
• Temple is developing a head-worn wearable that continuously monitors cerebral blood flow and brain activity. This next-generation device moves beyond wrist-worn fitness trackers, providing real-time insight into cognitive function, fatigue, and brain health for both elite athletes and general populations.
• Berlin-based YOU(th) closed a $4.5 million round for its smartphone-based health screening platform. Using AI and photoplethysmography, the platform analyzes face videos, voice recordings, and other sensors to assess 50 digital biomarkers in under two minutes, offering a scalable, longitudinal view of health outside the clinic.
• Mainstream pharma is also advancing longevity research. Richter acquired Celmatix’ ovarian biology assets to expand therapies targeting ovarian aging. Slowing ovarian decline could impact fertility, bone health, cardiovascular risk, and cognitive resilience, reinforcing women’s health as a central longevity focus.
• Data on billionaire longevity shows wealth alone offers minimal lifespan extension. Male billionaires live about four years longer than peers, while female billionaires have life expectancy below long-lived populations. The analysis highlights the importance of investing in scientific research over relying solely on lifestyle or capital.
• Finally, Swiss startup Xsensio is developing a nanotech-enabled continuous biosensing platform. This minimally invasive skin sensor tracks metabolites, electrolytes, and inflammatory markers in real time, offering a path toward proactive, biomarker-driven healthcare and continuous monitoring of intrinsic capacity.

_____________________

News & References:

• ARPA-H pours millions into healthspan-focused human trials → https://longevity.technology/news/arpa-h-pours-millions-into-healthspan-focused-human-trials
• Wearable startup Temple secures $54m for brain monitoring → https://longevity.technology/news/wearable-startup-temple-secures-54m-for-brain-monitoring/
• YOU(th) lands funding for smartphone-based preventive health screening → https://longevity.technology/news/youth-lands-funding-for-smartphone-based-preventive-health-screening/
• Richter sharpens ovarian aging focus following Celmatix asset deal → https://longevity.technology/news/richter-sharpens-ovarian-aging-focus-following-celmatix-asset-deal/
• How billionaires die → https://longevity.technology/news/how-billionaires-die/
• Nanotech startup lands funding for continuous biosensing platform → https://longevity.technology/news/nanotech-startup-lands-funding-for-continuous-biosensing-platform/

_____________________

Hosts:

Phil Newman: ⁠⁠⁠https://qrco.de/bgXpNY⁠⁠⁠

Nina Patrick: ⁠⁠⁠https://qrco.de/bgXpKn

Guests:

Allen Law

Founder and CEO of MORROW

Linkedin:https://www.linkedin.com/in/allenlawphg/

Website:https://morrow.health/

Dr William Tan

Clinical Governance Officer of MORROW

Linkedin: https://www.linkedin.com/in/dr-william-tan-05438649/

Website: https://morrow.health/

______________________

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.

Link:https://www.getstride.com/unlocked/

______________________

What if longevity wasn’t a treatment… but a system you live inside every day?

In this episode, Phil Newman sits down with Allen Law, founder and CEO of Morrow, and Dr William Tan, physician-neuroscientist and Chief Governance Officer of Morrow, to explore a new model of preventive healthcare designed around daily behavior, measurable biology, and community support.

They discuss why modern medicine often reacts to disease rather than preventing it, how lifestyle medicine can be structured into actionable programs, and why most people fail to act on their health data even after testing. Allen explains how Morrow combines diagnostics, coaching, and artificial intelligence to translate biomarkers into habits, while William shares how his personal journey through disability and elite sport shaped his philosophy of proactive health.

Together, they examine accessibility in longevity care, the economics of preventive medicine, and why community engagement may be as important as any clinical intervention. The conversation also looks at Singapore’s evolving health ecosystem and how technology could scale personalized care beyond elite clinics.

In this episode, you’ll learn:

• Why preventive healthcare often fails despite widespread testing
• How Morrow connects diagnostics directly to daily lifestyle interventions
• The role of AI in turning health data into consistent habit change
• Why community and purpose influence long term health outcomes
• How accessibility could reshape the longevity clinic industry
• What Singapore’s healthcare model reveals about future global systems
• Why small consistent habits outperform short term health resolutions

If you want to understand how healthcare may shift from treating illness to designing wellbeing, and what real world longevity infrastructure could look like, this conversation offers a practical view of the future of healthspan.

Subscribe for weekly episodes exploring longevity science, emerging biotech, and the innovations shaping the future of human health.

______________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest discoveries transforming longevity science. From invisible nanoplastics crossing the blood-brain barrier to first-of-its-kind Klothea mRNA human trials, wearable lactate sensors, and AI models targeting aging-linked inflammation, this episode connects science, innovation, and real-world impact.

• Recent research shows that nanoplastics, ultra-small fragments of degraded plastic closer in size to viruses than visible debris, are accumulating in human brain tissue. Age does not predict accumulation, and higher concentrations appear in tissues affected by Alzheimer’s and vascular dementia.
• Klothea has launched a phase 1b human trial for their AKL003 mRNA therapy, aiming to boost levels of the longevity-associated protein alpha-Klotho. Conducted in Prospera, Honduras, the study measures epigenetic clocks, inflammatory and metabolic markers, mitochondrial function, sleep, and patient-reported quality of life. This represents one of the first human longevity trials designed around lifespan as the primary endpoint rather than disease.
• In sports and metabolic monitoring, PointFit is developing a wearable sweat patch that continuously tracks lactate, cortisol, creatine, and glucose. Lactate serves as a real-time biomarker for exercise intensity and fatigue, bridging elite athlete optimization and general population healthspan. Early adoption is expected in high-performance sports, but applications in rehab and clinical aging are promising.
• Regulatory innovation continues with the FDA officially ending the “two trial dogma.” One pivotal, rigorously designed trial may now suffice for drug approval, lowering barriers for therapies targeting aging processes and biomarker-driven endpoints. This shift could shave three to five years off development timelines and reduce costs by tens of millions, accelerating the path for human longevity drugs.
• Finally, AI is moving from broad discovery to targeted intervention. Scienta Lab unveiled EVA, a multimodal AI platform mapping inflammatory networks tied to aging, aiming to design precision anti-inflammatory therapies. Rather than simply accelerating existing pharma pipelines, platforms like EVA could guide the development of highly personalized interventions tailored to an individual’s inflammatory signature, tissue context, and age.
• The Longevity Show has confirmed Hertility as Strategic Content and Scientific Lead Partner for the Women’s Health Summit at its inaugural 2026 event in London. Hertility will co-lead the scientific framing and programme development of the Summit. The partnership positions female biology not as a thematic sidebar, but as a structural lens through which longevity science and infrastructure must increasingly be designed.

______________________

News & References:

• Nanoplastics found in the brain raise new aging questions → https://longevity.technology/news/nanoplastics-found-in-the-brain-raise-new-aging-questions/
• Klothea initiates longevity-focused human trial of klotho therapy → https://longevity.technology/news/klothea-initiates-longevity-focused-human-trial-of-klotho-therapy/
• Seveno backs PointFit wearable patch → https://longevity.technology/news/seveno-backs-pointfit-wearable-patch/
• FDA rewrites drug approval rules and longevity stands to gain → https://longevity.technology/news/fda-rewrites-drug-approval-rules-and-longevity-stands-to-gain/
• Scienta’s new AI model targets aging-linked inflammation → https://longevity.technology/news/scientas-new-ai-model-targets-aging-linked-inflammation/
• Hertility announced as Women’s Health Partner for Longevity Show → https://longevity.technology/news/hertility-announced-as-womens-health-partner-for-longevity-show/

______________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Guest: Alexander Zhavoronkov

Founder, CEO and CBO at Insilico Medicine

Linkedin: www.linkedin.com/in/zhavoronkov/

Website: https://insilico.com/

______________________

What if the biggest breakthrough in longevity wasn’t a single drug… but a faster way to discover them?

In this episode, Phil Newman and Dr Nina Patrick sit down with Alex Zhavoronkov, founder and CEO of Insilico Medicine, to explore how artificial intelligence is reshaping biotechnology, from target discovery to clinical trials.

They discuss why advanced diagnostics may currently outperform most longevity interventions, how AI platforms design entirely new molecules, and why no longevity drug has yet proven efficacy in humans despite promising animal data. Alex explains how modern biotech companies balance aging research with traditional disease treatment, and why the first real longevity therapeutics will likely emerge as side benefits of drugs built for specific conditions.

Together, they examine the reality behind GLP-1 drugs, long term safety testing, and the limits of predictive algorithms. The conversation also looks ahead to brain computer interfaces, multimodal biological models, and the possibility of pharmaceutical superintelligence accelerating medical progress within the next decade.

In this episode, you’ll learn:

• Why early diagnostics may currently be the most reliable longevity strategy.
• How AI can design drug candidates in months instead of years.- Why most longevity drugs succeed in animals but fail to prove benefits in humans.
• How disease focused therapeutics could become future aging interventions.
• What GLP-1 drugs reveal about the future of longevity medicine.
• The real role of clinical trials in validating AI generated therapies.
• How next generation technologies like brain computer interfaces could extend healthy lifespan.

If you want to understand how artificial intelligence is changing medicine, what real longevity therapeutics may look like, and why the future of healthspan depends on both biology and computation, this is a conversation you don’t want to miss.

Subscribe for weekly episodes exploring longevity science, emerging biotech, and the innovations shaping the future of human health.

______________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalized DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.

Link: https://www.getstride.com/unlocked/

______________________

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest breakthroughs shaping healthspan and longevity. From oral GLP-1 pills transforming obesity and metabolic care, to early gene therapy results in aging dogs, and Amazon integrating biomarker-driven longevity insights into primary care, this episode covers innovation, risk, and opportunity across human and animal longevity.

• Novo Nordisk and Eli Lilly are moving forward with oral versions of their GLP-1 drugs, potentially bringing millions more patients onto treatment. Pills are easier to access than injections, but counterfeiting risks are rising. GLP-1 therapies are evolving beyond weight loss into long-term metabolic health interventions, targeting cardiovascular, joint, and chronic pain outcomes.
• London-based GenFlow Biosciences released preliminary data from its SIRT6 gene therapy in aged dogs. All treatment groups showed improved survival, muscle mass, and frailty scores. This dual approach addresses companion animal health while acting as a translational model for human aging interventions.
• In digital health, Amazon One Medical is rolling out biomarker-driven insights powered by LifeForce’s longevity platform. This signals a growing shift in how consumer and clinical longevity data will influence behavior, outcomes, and healthcare delivery.
• In consumer trends, global PR firm Edelman highlights the rise of the longevity generation. Their Longevity Lab initiative shows that people 55 and older control more than half of global consumer spending, yet receive only a fraction of marketing budgets. Brands are beginning to rethink products, campaigns, and services for older, active, high-spending consumers, a growing business opportunity in the health, finance, hospitality, and lifestyle sectors.
• Israeli neurotech company QuantalX launched the Delphi MD system in the US, a non-invasive brain function assessment combining transcranial magnetic stimulation, EEG, and AI analytics. Already deploying at Penn, Mass General, UCSF, and UT Dallas, the test has a reimbursement code, potentially shifting brain health monitoring from reactive to preventative care.
• Gimv, a European investment firm, signaled a pullback from early-stage aging biotech, citing long timelines and unpredictable ROI. Capital is now shifting toward technology-enabled services, diagnostics, and digital longevity platforms where returns are faster and more measurable.

______________________

News & References:

• What Gimv’s biotech pullback says about aging markets → https://longevity.technology/news/what-gimvs-biotech-pullback-says-about-aging-markets/
• Are global brands ready for longevity? → https://longevity.technology/news/are-global-brands-ready-for-longevity/
• New functional brain assessment system rolls out in the US → https://longevity.technology/news/new-functional-brain-assessment-system-rolls-out-in-the-us/
• As obesity drugs go oral and access grows, so do fakes → https://longevity.technology/news/as-obesity-drugs-go-oral-and-access-grows-so-do-fakes/
• Genflow reveals early data from SIRT6 gene therapy trial in dogs → https://longevity.technology/news/genflow-reveals-early-data-from-sirt6-gene-therapy-trial-in-dogs/
• Amazon makes longevity move with Lifeforce collab → https://longevity.technology/news/amazon-makes-longevity-move-with-lifeforce-collab/

______________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠